Enterprise Financial Services Corp (EFSC)’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-64
Closed -$7K 1323
2019
Q4
$7K Hold
64
﹤0.01% 799
2019
Q3
$6K Sell
64
-6,000
-99% -$561K ﹤0.01% 822
2019
Q2
$511K Hold
6,064
0.11% 121
2019
Q1
$535K Buy
6,064
+6,000
+9,375% +$501K 0.12% 120
2018
Q4
$5K Hold
64
﹤0.01% 660
2018
Q3
$8K Buy
+64
New +$7.26K ﹤0.01% 644
2017
Q2
Sell
-23
Closed -$1K 1006
2017
Q1
$1K Sell
23
-42
-65% -$1.8K ﹤0.01% 1022
2016
Q4
$3K Sell
65
-150
-70% -$6.79K ﹤0.01% 852
2016
Q3
$11K Hold
215
0.01% 545
2016
Q2
$10K Buy
+215
New +$9.9K 0.01% 549
2016
Q1
Sell
-257
Closed -$15K 1107
2015
Q4
$15K Hold
257
0.01% 472
2015
Q3
$10K Buy
+257
New +$12.4K 0.01% 541

Other funds holding NBIX

Enterprise Financial Services Corp (EFSC)'s NBIX Position: Q1 2020 in Review

Enterprise Financial Services Corp (EFSC) sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 64 shares — an estimated $7K sold.

Enterprise Financial Services Corp (EFSC) first reported a position in NBIX in Q3 2015 and held it in 12 quarters. The position peaked at $535K in Q1 2019. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Enterprise Financial Services Corp (EFSC) reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Enterprise Financial Services Corp (EFSC) sold 64 Neurocrine Biosciences shares in Q1 2020, an estimated $7K.
  • Enterprise Financial Services Corp (EFSC) first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 12 quarters.
  • Enterprise Financial Services Corp (EFSC)'s Neurocrine Biosciences position peaked at $535K in Q1 2019.
  • 368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Enterprise Financial Services Corp (EFSC)'s 13F filing for Q1 2020, filed 15 May 2020.